Company intelligence / Profile preview

Hunter Immunology

Sydney, New South Wales, Australia

Ownership: Private
Development stage: Other

Overview

Hunter Immunology's lead program, HI-164OV (an oral vaccine based on inactivated Haemophilus influenzae), showed positive Phase IIa results in reducing hospital admissions for moderate-to-severe COPD, with a Phase IIb trial of 320 patients completed, top-line results anticipated in early 2012. The technology platform aims to reduce respiratory exacerbations with potential applications in asthma.

Therapeutic areas: Pulmonology
Modalities: VaccineBiologic
Industry: Biotech

Beyond the preview

Go deeper on Hunter Immunology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hunter Immunology.

Explore the full profile